<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(1)</volume><submitter>Pirmani A</submitter><pubmed_abstract>Early prediction of disability progression in multiple sclerosis (MS) remains challenging despite its critical importance for therapeutic decision-making. We present the first systematic evaluation of personalized federated learning (PFL) for 2-year MS disability progression prediction, leveraging multi-center real-world data from over 26,000 patients. While conventional federated learning (FL) enables privacy-aware collaborative modeling, it remains vulnerable to institutional data heterogeneity. PFL overcomes this challenge by adapting shared models to local data distributions without compromising privacy. We evaluated two personalization strategies: a novel AdaptiveDualBranchNet architecture with selective parameter sharing, and personalized fine-tuning of global models, benchmarked aga</pubmed_abstract><journal>NPJ digital medicine</journal><pagination>478</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12289948</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data.</pubmed_title><pmcid>PMC12289948</pmcid><pubmed_authors>Alroughani R</pubmed_authors><pubmed_authors>Singhal B</pubmed_authors><pubmed_authors>Kalincik T</pubmed_authors><pubmed_authors>Kuhle J</pubmed_authors><pubmed_authors>John N</pubmed_authors><pubmed_authors>Cauchi M</pubmed_authors><pubmed_authors>Guimaraes J</pubmed_authors><pubmed_authors>Garber J</pubmed_authors><pubmed_authors>De Brouwer E</pubmed_authors><pubmed_authors>Peeters LM</pubmed_authors><pubmed_authors>Willekens B</pubmed_authors><pubmed_authors>Rajda C</pubmed_authors><pubmed_authors>Hughes S</pubmed_authors><pubmed_authors>Tomassini V</pubmed_authors><pubmed_authors>Maimone D</pubmed_authors><pubmed_authors>Sas A</pubmed_authors><pubmed_authors>Lugaresi A</pubmed_authors><pubmed_authors>Taylor B</pubmed_authors><pubmed_authors>Van Wijmeersch B</pubmed_authors><pubmed_authors>Al-Asmi A</pubmed_authors><pubmed_authors>Sirbu CA</pubmed_authors><pubmed_authors>McCombe P</pubmed_authors><pubmed_authors>Castillo Trivino T</pubmed_authors><pubmed_authors>Havrdova EK</pubmed_authors><pubmed_authors>Passemiers A</pubmed_authors><pubmed_authors>Ozakbas S</pubmed_authors><pubmed_authors>de Gans K</pubmed_authors><pubmed_authors>Carroll WM</pubmed_authors><pubmed_authors>Pirmani A</pubmed_authors><pubmed_authors>Buzzard K</pubmed_authors><pubmed_authors>Hardy TA</pubmed_authors><pubmed_authors>Lalive P</pubmed_authors><pubmed_authors>Perez-Sempere A</pubmed_authors><pubmed_authors>Moreau Y</pubmed_authors><pubmed_authors>Ramanathan S</pubmed_authors><pubmed_authors>Van Pesch V</pubmed_authors><pubmed_authors>Rozsa C</pubmed_authors><pubmed_authors>Amato MP</pubmed_authors><pubmed_authors>Solaro C</pubmed_authors><pubmed_authors>Grammond P</pubmed_authors><pubmed_authors>Shuey N</pubmed_authors><pubmed_authors>Prat A</pubmed_authors><pubmed_authors>Boz C</pubmed_authors><pubmed_authors>Horakova D</pubmed_authors><pubmed_authors>Oldenhof M</pubmed_authors><pubmed_authors>Csepany T</pubmed_authors><pubmed_authors>Mason D</pubmed_authors><pubmed_authors>Blanco Y</pubmed_authors><pubmed_authors>Fabis-Pedrini M</pubmed_authors><pubmed_authors>Decoo D</pubmed_authors><pubmed_authors>Patti F</pubmed_authors><pubmed_authors>Cartechini E</pubmed_authors><pubmed_authors>Faes A</pubmed_authors><pubmed_authors>Arany A</pubmed_authors><pubmed_authors>Gouider R</pubmed_authors><pubmed_authors>Gerlach O</pubmed_authors><pubmed_authors>Lechner-Scott J</pubmed_authors><pubmed_authors>Simu M</pubmed_authors><pubmed_authors>Roos I</pubmed_authors><pubmed_authors>Laureys G</pubmed_authors><pubmed_authors>Altintas A</pubmed_authors><pubmed_authors>Spitaleri D</pubmed_authors><pubmed_authors>Kermode AG</pubmed_authors><pubmed_authors>Al-Harbi T</pubmed_authors><pubmed_authors>Prevost J</pubmed_authors><pubmed_authors>Gray O</pubmed_authors><pubmed_authors>Van der Walt A</pubmed_authors><pubmed_authors>Butzkueven H</pubmed_authors><pubmed_authors>Khoury SJ</pubmed_authors><pubmed_authors>Soysal A</pubmed_authors><pubmed_authors>Sanchez-Menoyo JL</pubmed_authors><pubmed_authors>Weinstock-Guttman B</pubmed_authors><pubmed_authors>Ampapa R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data.</name><description>Early prediction of disability progression in multiple sclerosis (MS) remains challenging despite its critical importance for therapeutic decision-making. We present the first systematic evaluation of personalized federated learning (PFL) for 2-year MS disability progression prediction, leveraging multi-center real-world data from over 26,000 patients. While conventional federated learning (FL) enables privacy-aware collaborative modeling, it remains vulnerable to institutional data heterogeneity. PFL overcomes this challenge by adapting shared models to local data distributions without compromising privacy. We evaluated two personalization strategies: a novel AdaptiveDualBranchNet architecture with selective parameter sharing, and personalized fine-tuning of global models, benchmarked aga</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jul</publication><modification>2026-03-27T17:04:07.93Z</modification><creation>2025-08-28T03:08:54.013Z</creation></dates><accession>S-EPMC12289948</accession><cross_references><pubmed>40707601</pubmed><doi>10.1038/s41746-025-01788-8</doi></cross_references></HashMap>